- Molecular NameMesoridazine
- SynonymThioridazien Thiomethyl Sulfoxide; Thioridazine Monosulfoxide Analog; Thioridazine Thiomethyl Sulfoxide; TPS-23; TPS23
- Weight386.584
- Drugbank_IDDB00933
- ACS_NO5588-33-0
- Show 3D model
- LogP (experiment)4.485
- LogP (predicted, AB/LogP v2.0)4.59
- pkaN/A
- LogD (pH=7, predicted)2.29
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.4
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA68.06
- StatusFDA approved; US withdrawn
- Administrationoral, intravenous
- PharmacologyA piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia.
- Absorption_valueN/A
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding4.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe major metabolite is sulforidazine which is pharmacologically active. Mesoridazine is a major metabolite of thioridazine.
- Half lifemesoridazine 2~9 h (mean 5), sulforidazine 6~25 h (mean 13).
- ExcretionBiliary and renal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn a fatality attributed to the ingestion of 2.5 g, the following postmortem tissue concentrations were reported: blood 3 mg/L, kidney 17 μg/g, liver 114 μg/g; in a second case in which 8 g had been ingested, the postmortem blood concentration was 4 mg/L [P. T. Donlon and J. P. Tupin,Arch. Gen. Psychiatry,1977, 34, 955–957].
- LD50 (rat)LD50=644 mg/kg
- LD50 (mouse)LD50=560 mg/kg